Enhancer defects in acute myeloid leukemia (AML): The Evil-side of gene regulation

Ruud Delwel
Erasmus MC hospital [Rotterdam, Netherlands]
07/02/2019 to 01/01/0001
Time: 12:30:00
Salón de actos del Centro de Investigación del Cáncer
Acute myeloid leukemias (AML) with an inv(3)(q21;q26) or t(3;3)(q21;q26) overexpress EVI1 and have a very poor prognosis. EVI1 is part of the MECOM (MDS1-EVI1 Combination) locus from which the long form MDS1-EVI1 and the short form EVI1 are transcribed from two different promoters. Although EVI1 is expressed at high levels, MDS1-EVI1 is absent or